Multiple Sclerosis Clinical Trials in Chicago
View 37 new treatments for Multiple Sclerosis in Chicago, IL, and other areas near me, such as Naperville. Every day, Power helps hundreds of Multiple Sclerosis patients connect with leading medical research.Frexalimab for Multiple Sclerosis
Sanofi Clinic, Northbrook + 2 more
This trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.Show More
Verified
Frexalimab for Multiple Sclerosis
Sanofi Clinic, Northbrook + 2 more
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: This event-driven study will have variable duration ranging from approximately 27 to 51 months. The study intervention duration will vary ranging from approximately 27 to 51 months. The number of scheduled visits will be up to 27 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months.Show More
Verified
Exercise Training for Depression in Multiple Sclerosis
Research Clinic, Chicago + 1 more
The purpose of this research is to examine the effects of two different exercise training regimens for managing depression and improving other health indicators among persons with multiple sclerosis (MS). The project will enroll persons with MS and major depressive disorder (MDD) between 18 and 64 years of age. The investigators will enroll a total of 146 participants. This is a Phase-II trial that compares the efficacy of an exercise training program (POWER-MS) compared with a stretching program (FLEX-MS) for immediate and sustained reductions in the severity of depression among persons with MS who have MDD.Show More
Verified
No Placebo Trial
Liraglutide for Obesity
Research Clinic, Chicago + 1 more
This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life. By doing this study, researchers hope to learn how liraglutide (Saxenda®), a weight loss drug, affects levels of a certain disease marker in the body called Brain Derived Neurotrophic Factor (BDNF). Participation in this research will last about 21 weeks.Show More
No Placebo Trial
Ocrelizumab Exposure During Pregnancy for Multiple Sclerosis
Hoffmann-La Roche Clinic, Chicago + 1 more
This trial will study how a medication for multiple sclerosis transfers from pregnant women to their babies. The focus is on women who took the medication around the time of pregnancy. Researchers will look at how this affects the baby's immune cells and overall health.Show More
No Placebo Trial
EMR-Based Treatment for Neurological Disorders
Research Clinic, Evanston + 1 more
The investigators will conduct at NorthShore University HealthSystem pragmatic trials using the EMR for 10 common neurological disorders. They will demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and outcomes data capture at the point of care using the EMR. They will identify the most effective treatments for common neurological disorders and seek replication by the NPBRN.Show More
No Placebo Trial
High-Dose Ocrelizumab for Multiple Sclerosis
Hoffmann-La Roche Clinic, Chicago + 1 more
This trial is testing if a higher dose of ocrelizumab given through an IV drip is more effective and safe for patients with Primary Progressive Multiple Sclerosis (PPMS). The drug works by reducing harmful immune cells to potentially slow down the disease. Ocrelizumab is the first drug approved for treating both relapsing and primary progressive forms of multiple sclerosis.Show More
No Placebo Trial
IMU-838 for Multiple Sclerosis
Immunic Clinic, Northbrook + 1 more
This trial is testing IMU-838, a medication for adults with relapsing multiple sclerosis. The drug aims to reduce immune system activity to prevent nerve damage and manage symptom flare-ups.Show More
Ozanimod for Multiple Sclerosis
Celgene Clinic, Hoffman Estates + 3 more
This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years. All subjects will receive orally administered ozanimod HCl 1 mg. The primary efficacy endpoint is the proportion of subjects with a clinically meaningful increase in raw score of ≥ 4 points or 10% from baseline (improved). The treatment period is 36 months. For all subjects who finish the subject and for those who discontinue, there will be a 30-day (± 15 days) and a 90-day (± 10 days) Safety Follow-up Visit. There is no planned protocol extension following the end of the study. Approximately 250 subjects with RMS will be recruited for this study. Subjects with RMS will be enrolled in this study if they have received ≤ 1 DMT, have an EDSS ≤ 3.5, and have been diagnosed with RMS within 5 years of study entry. The Investigator will be responsible for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS relapses, and management of AEs.Show More
No Placebo Trial
Fenebrutinib for Relapsing Multiple Sclerosis
Hoffmann-La Roche Clinic, Highland Park + 1 more
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.Show More
Frequently Asked Questions
How much do multiple sclerosis clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.
Do I need to be insured to participate in a medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
How do multiple sclerosis clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across multiple sclerosis trials in Chicago, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for multiple sclerosis patients is 6 Months.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.
Where in Chicago is research being conducted for multiple sclerosis?
Prominent hospitals in Chicago conducting multiple sclerosis clinical trials include the University of Illinois at Chicago and Shirley Ryan AbilityLab. Approximately 14 trials are ongoing as of 2024, primarily in the central area of the city.
What promising new drugs are being tested?
In Chicago, multiple sclerosis research is focusing on treatments like Monoclonal Antibodies and Immunomodulators. Notable drugs being studied include Ocrelizumab, Fingolimod, and Teriflunomide.